Tonix Pharmaceuticals Holding Corp (TNXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.49M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tonix Pharmaceuticals Holding Corp (TNXP) Stock Forecast
Analysts expect Tonix Pharmaceuticals Holding (TNXP) to earn -$10.92 per share in the fiscal year ending Dec 31, 2026, on revenue of $57.51M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 96.2%.
- Fiscal year ending Dec 31, 2026
- -$10.92
- EPS consensus, revenue $57.51M
- Fiscal year ending Dec 31, 2027
- -$7.00
- EPS consensus, revenue $112.81M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$10.92 | -$11.10 to -$10.73 | 2 | $57.51M | $57.22M to $57.80M | 2 |
| Dec 31, 2027 | -$7.00 | -$8.25 to -$4.86 | 3 | $112.81M | $93.44M to $149.00M | 5 |
Quarterly Estimates
The EPS consensus falls from -$2.41 for the quarter ending Dec 31, 2026 to -$2.42 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.41 | -$2.45 to -$2.39 | 8 | $20.70M | $16.17M to $24.15M | 8 |
| Mar 31, 2027 | -$2.42 | -$2.42 to -$2.42 | 1 | $23.25M | $17.50M to $29.00M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$9.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$10.92 | -$9.78 | -$9.95 | -$9.95 | -$9.95 | N/A |
| Fiscal year ending Dec 31, 2027 | -$7.00 | -$6.82 | -$7.88 | -$7.88 | -$7.88 | N/A |
| Quarter ending Mar 31, 2027 | -$2.42 | -$2.20 | -$2.20 | -$2.20 | -$2.20 | N/A |
Frequently Asked Questions About TNXP
What is the TNXP stock forecast?
Consensus analyst estimates put Tonix Pharmaceuticals Holding's EPS at -$10.92 for the fiscal year ending Dec 31, 2026, on revenue of $57.51M. The consensus rating from 4 analysts is Buy.
How do analysts rate TNXP stock?
Of 4 analysts covering Tonix Pharmaceuticals Holding, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TNXP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$10.92, with estimates from -$11.10 to -$10.73 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$7.00, with estimates from -$8.25 to -$4.86 from 3 analysts.
What revenue do analysts expect from Tonix Pharmaceuticals Holding next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $57.51M, with estimates from $57.22M to $57.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $112.81M, with estimates from $93.44M to $149.00M.
How many analysts cover TNXP?
4 analysts rate Tonix Pharmaceuticals Holding stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TNXP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors